Merrimack Pharmaceuticals' (NASDAQ:MACK) IPO debuted with a thud this past summer, falling 14% intraday from its $7 listing price. The biopharmaceuticals company focuses on innovative treatments for serious conditions with a primary focus on cancers. The product pipeline includes a promising lead drug and a secondary drug backed by Sanofi (NYSE:SNY). But the company's trading nearly 13% below its list price.
Here are three things to watch when considering Merrimack.
1. Lead drug
MM-398 began phase 3 trials this past summer for treatment-resistant pancreatic cancer. The Food and Drug Administration granted the drug orphan status. Additional early stage trials will examine its efficacy with colorectal cancer and gliomas -- or tumors beginning in the brain or spinal cord.
Transparency Market Research estimates that the domestic pancreatic cancer market will hit $1.2 billion by 2015. The leading treatment has historically been Eli Lilly's (NYSE:LLY) chemo drug Gemzar. But a rising new wave of treatments, including Merrimack and Celgene's (NASDAQ:CELG) Abraxane, offers options for patients for whom Gemzar wasn't enough .
Merrimack paid up to have a chance in this market. The company acquired MM-398's original developer in 2009 . Last year, Merrimack agreed to pay up to $220 million in up-front and milestone payments to PharmaEngine for overseas marketing rights. PharmaEngine, the drug's collaborator, will retain rights in its home country of Taiwan.
2. Secondary drug
MM-121 is involved in three phase 2 trials, one phase 1/2 trial, and four phase 1 trials. Those trials include several types of cancers such as breast and lung. It is an ambitious drug for a small company but benefits from having Sanofi as a backer.
Sanofi made a $60 million up-front payment and a series of milestone payments for its share of MM-121. More milestones and potential royalty payments could follow. Sanofi is responsible for the manufacturing and development costs. Merrimack will participate through phase 2 and has the option to co-promote the drug in the U.S. upon its release.
3. Cash burn
Merrimack's cash burn for the most recent quarter was around $21 million . The company reported about $87 million in cash, cash equivalents, and short-term investments. Combine that with a new loan agreement with a $40 million limit, and Merrimack can probably sustain itself until 2014, when revenues should start flowing.
It will be some time before late-stage trials report and show a clearer picture of Merrimack's standing. MM-398 will need to show strength in a market that's becoming increasingly crowded. MM-121 could become the underdog champion, especially with Sanofi's contribution. It might benefit investors to take a "wait and see" approach with Merrimack until more data arrives.
Brandy Betz has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.